Agriculture ministers commit to global tra...Ministers from 72 countries came together at the Berlin Agriculture Ministers’ conference to discuss and adopt a joint communiqué on global trade. In it, the ministers agreed to strengthen rule-based … more ➔
HepaRegeniX: €11m for liver disease trea...HepaRegeniX has raised €11m in a Series B. The biotech company will use the proceeds to bring its compound targeting chronic liver disease to the clinic. more ➔
Nestlé heavily invests in sustainable pac... Swiss food giant Nestlé will invest up to €1.68bn to support sustainable packaging solutions and to create a market for plastic-free or recycled alternatives. more ➔
BioNTech acquires Neon at cheapest for $67...mRNA cancer neoantigen specialist BioNTech AG is set to buy all shares of Neon Therapeutics, Inc. expanding its pipeline of neoantigen-targeting therapies and getting foothold in the US. more ➔
New stromal target overcomes cancer resist...British researchers have identified several small molecule drugs that sensitized B cell cancers to chemotherapy and extended survival in mouse models. more ➔
Astellas and Adaptimmune team up in CAR-T...Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells. more ➔
Illumina embraces RocheTwelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. more ➔
Incyte licenses Morphosys’ tafasitam...Incyte Corp. has signed a global license agreement for commercialisation of Morphosys AG’s anti-CD-19 programme tafasitamab. more ➔
Novadiscovery takes off with €5 Series A...In silico clinical trials pioneer Novadiscovery SA has raised €5m in a series A financing led by Swiss Debiopharm Innovation Fund. more ➔
Alderaan Biotechnology raise €18.5m in S... Following a €1.5m seed financing in 2017, cancer specialist Alderaan Biotechnology SAS has raised €18.5m in a Series A round led by Advent France Biotechnology and Medicxi. more ➔
